Document is current
Any future updates will be listed below
-
Authors
Yazdi, Narjes
Pourjamal, Negar
Li, Hao
Laakkonen, Pirjo
Joensuu, Heikki
Barok, Mark https://orcid.org/0000-0002-9585-7669
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 4 July 2025
Accepted: 22 February 2026
First Online: 3 March 2026
Declarations
:
: The Committee for animal experiments of the District of Southern Finland approved the animal experiments under the licenses ESAVI/403/2019, ESAVI/11614/2022, and ESAVI/10262/2022. The reporting in the manuscript follows the recommendations in the ARRIVE guidelines (https://arriveguidelines.org/arrive-guidelines).
: Not applicable.
: H.J. is the Chair of the Scientific Advisory Board of Orion Pharma, Neutron Therapeutics, and Maud Kuistila Foundation, from which work he has received financial compensation, and owns stock of Orion Pharma and Sartar Therapeutics. M.B. has an advisory relationship at ProBiont Ltd. M.B. and H.J. report grants from Defense Therapeutics Inc. and Merck KGaA outside the submitted work. No potential conflicts of interest were disclosed by the other authors.
